Equillium (EQ) Income towards Parent Company (2018 - 2026)
Equillium (EQ) reported Income towards Parent Company of -$5.3 million for Q1 2026, up 39.05% year-over-year from -$3.8 million in Q1 2025, and down 134.71% on a QoQ basis from $15.3 million in Q4 2025.
Equillium (EQ) has 9 years of Income towards Parent Company data on file, last reported at -$5.3 million in Q1 2026.
- Quarterly Income towards Parent Company rose 39.05% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$476000.0 (up 96.61% YoY) and the FY2025 annual result came in at -$22.4 million, down 177.65% from the prior year.
- Income towards Parent Company declined to -$5.3 million in Q1 2026 per EQ's latest filing, from $15.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $63.2 million in Q4 2022 and bottomed at -$37.4 million in Q1 2022.
- The 5-year median for Income towards Parent Company is -$3.9 million (2023), against an average of -$1.9 million.
- The widest annual swing landed in 2022, when Income towards Parent Company surged 693.59%; it then sank 61900.0% in 2025.
- Tracing EQ's Income towards Parent Company over 5 years: stood at $63.2 million in 2022, then plunged by 103.68% to -$2.3 million in 2023, then slumped by 149.1% to -$5.8 million in 2024, then soared by 363.57% to $15.3 million in 2025, then plunged by 134.71% to -$5.3 million in 2026.
- Per Business Quant, the three latest EQ Income towards Parent Company figures stand at -$5.3 million (Q1 2026), $15.3 million (Q4 2025), and -$4.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.30 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.70 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -2.33 Mn |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.94 Mn |
| Dec 31, 2022 | 63.18 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -10.12 Mn |
| Jun 30, 2021 | -9.10 Mn |
| Mar 31, 2021 | -8.94 Mn |
| Dec 31, 2020 | -9.19 Mn |
| Sep 30, 2020 | -6.71 Mn |
| Jun 30, 2020 | -6.76 Mn |
| Mar 31, 2020 | -7.51 Mn |
| Dec 31, 2019 | -7.60 Mn |
| Sep 30, 2019 | -6.00 Mn |
| Jun 30, 2019 | -6.06 Mn |
| Mar 31, 2019 | -5.95 Mn |
| Dec 31, 2018 | -4.17 Mn |
| Sep 30, 2018 | -3.42 Mn |
| Jun 30, 2018 | -1.72 Mn |
| Mar 31, 2018 | -1.52 Mn |